AI filing briefs · archive

8-K filings in October 2025, explained

1,152 material Form 8-K filings that 918 companies we cover made with the SEC in October 2025, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).

2 of 1,152 briefs match

newest first · times in ET

STZCONSTELLATION BRANDS, INC. Oct 6, 4:08 PM ET

Constellation Brands reports fiscal Q2 2025 results for quarter ended August 31, 2025

Neutral earnings Written later 2.02 7.01

Constellation Brands furnished an October 6, 2025 news release covering its second fiscal quarter ended August 31, 2025, as Exhibit 99.1 to this Form 8-K. The filing text provided does not state any revenue, profit, EPS or guidance figures, so the direction of results cannot be judged from it. Shareholders should review Exhibit 99.1 for the reported numbers and any updated guidance.

News release dated October 6, 2025 covers the quarter ended August 31, 2025
Release includes forward-looking guidance that the company says could vary materially from actual results
Release includes non-GAAP measures (comparable, adjusted, organic) with reconciliations to GAAP
Report signed by Garth Hankinson, Executive Vice President and Chief Financial Officer

Read the filing on SEC.gov ↗

REGNREGENERON PHARMACEUTICALS, INC. Oct 6, 7:00 AM ET

Regeneron expects $83 million Q3 2025 charge, cutting EPS by about $0.68

Negative earnings Written later 2.02

Regeneron said its preliminary third quarter 2025 GAAP and non-GAAP results will include an acquired in-process research and development charge of about $83 million before taxes. The charge mainly relates to the previously disclosed $80 million up-front payment to Hansoh Pharmaceuticals under a 2025 license agreement, and is expected to reduce net income per diluted share by about $0.68. The figures are unaudited and not yet final, so actual results could differ.

Expected acquired IPR&D charge of about $83 million pre-tax for the quarter ended September 30, 2025
Charge mainly relates to the $80 million up-front payment to Hansoh Pharmaceuticals Group under the 2025 license agreement
Expected impact of about $0.68 per diluted share on both GAAP and non-GAAP net income
Results are preliminary and subject to financial statement closing procedures

Read the filing on SEC.gov ↗

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.

Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.